Grepafloxacin

Summary

Grepafloxacin (CHEMBL583) is an approved small molecule (ATC J01MA11); indicated across 2 conditions including bacterial infectious disease and osteomyelitis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J01MA11
• Indications: 2 conditions
• Chemistry: 359.4 Da · C19H22FN3O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL583
Name	Grepafloxacin
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	72474
ATC	J01MA11
Molecular formula	C19H22FN3O3
Molecular weight	359.4
InChIKey	AIJTTZAVMXIJGM-UHFFFAOYSA-N

SMILES: CC1CN(CCN1)C2=C(C(=C3C(=C2)N(C=C(C3=O)C(=O)O)C4CC4)C)F

IUPAC name: 1-cyclopropyl-6-fluoro-5-methyl-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid

Also known as: Grepafloxacin, Grepafloxacine, Grepafloxacino, grepafloxacin, SID50112780, GREPAFLOXACINE, GREPAFLOXACIN

Parent form; salt/anhydrous children: CHEMBL1200393

Patent coverage: 2,898 distinct patent families (11,184 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 11,181 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Voltage-gated inwardly rectifying potassium channel KCNH2, Histamine H3 receptor.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 9 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
HRH3	5.37	AC50	4257	nM	CHEMBL_ACT_25199502

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
bacterial infectious disease	4	MONDO:0005113	EFO:0000771
osteomyelitis	0	MONDO:0005246	EFO:0003102

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).